Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 152

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 152
---
 involve immune effector cells other than T cells, such as CAR-NK and CAR-M therapies, are unlikely to enjoy similar
benefits.

<div align='center'>84</div>

In preclinical studies,
we have observed CER-1236 to display attractive functional attributes, among which are:

| ● | target-dependent                                                                           
 activation, cytotoxicity, anti-tumor cytokine production, and high proliferative capacity; |

| ● | phagocytosis    
 of tumor cells; |

| ● | distinct                                                                                      
 transcriptome, cytokine and chemokine signatures that substantiate the complementary activity 
 of both the innate and adaptive immune response;                                              |

| ● | enhanced                                          
 antigen acquisition, processing and presentation; |

| ● | no                                                         
 evidence of T cell exhaustion despite repeated challenges; |

| ● | no                                           
 observed off-target or off-tumor toxicities; |

| ● | expression                                                                              
 and maintenance of diverse T cell populations, including naïve and memory cells, likely 
 indicative of response persistence and durability; and                                  |

| ● | well                                          
 defined and scalable manufacturing protocols. |

Based on the preclinical
data regarding the use of CER-1236 T cells to combat hematologic malignancies, we anticipate beginning clinical trials in the first half
of 2025. We anticipate that our initial targets will be relapsed, remitting acute myeloid leukemia (“AML”) patients as well
as AML patients with measurable residual disease (“MRD”) and patients with mutations in TP53, a gene mutation associated
with aggressive AML. AML is a heterogenous and aggressive hematopoietic malignancy characterized by the rapid buildup of immature myeloid
cells in the bone marrow and blood. This process results in the inhibition of normal haematopoiesis, manifesting as neutropenia, anemia,
thrombocytopenia, and the clinical features of bone marrow failure. AML accounts for 90% of all acute leukemias in adults, with an estimated
20,800 new cases and 11,220 deaths expected in the United States in 2023. The current treatment has remained largely unchanged over several
decades with combination chemotherapy with cytarabine for 7 days and an anthracycline for 3 days (“7+3”). Newer, targeted
approaches that include multi-kinase domain inhibitors and antibody-drug conjugates are now available during induction chemotherapy for
certain patients. For